Literature DB >> 30610361

Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?

Masafumi Yamaguchi1, Shinichiro Shimamatsu2, Makoto Edagawa2, Fumihiko Hirai2, Ryo Toyozawa2, Kaname Nosaki2, Takashi Seto2, Mitsuhiro Takenoyama2, Yukito Ichinose2.   

Abstract

PURPOSE: We conducted a retrospective analysis to assess the practicality of pneumonectomy, especially after concurrent induction chemoradiotherapy (i-CRT), for locally advanced non-small cell lung cancer (LA-NSCLC). The operative risks vs. the survival benefit of this procedure for such patients is a subject of controversy.
METHODS: The subjects of this retrospective study were 71 consecutive LA-NSCLC patients with cStage IIIA-C NSCLC, who underwent i-CRT followed by curative intent pulmonary resection between February, 2001 and March, 2013.
RESULTS: Thirty-two patients underwent pneumonectomy (group P) and 39 patients underwent lobectomy (group L). In group P, 17 (54.8%) patients underwent right pneumonectomy. There was no 30-day postoperative mortality in either group and no significant difference in 90-day postoperative mortality between the groups (3.1% vs. 2.6% in groups P and L, respectively). The 5-year overall survival (OS) rate was 58.7% (95% CI: 41.5-75.9%) in group P and 57.3% (95% CI 41.2-73.4%) in group L, without a significant difference between the groups.
CONCLUSION: Our findings suggest that i-CRT followed by pneumonectomy is feasible, with a similar survival benefit to lobectomy. Thus, pneumonectomy after i-CRT should not be avoided as it is a potentially curative intent strategy for carefully selected patients.

Entities:  

Keywords:  Induction chemoradiotherapy; Locally advanced non-small cell lung cancer; Pneumonectomy

Mesh:

Year:  2019        PMID: 30610361     DOI: 10.1007/s00595-018-1751-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  1 in total

1.  Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.

Authors:  Pieter J M Joosten; Chris Dickhoff; Vincent van der Noort; Maarten Smeekens; Rachel C Numan; Houke M Klomp; Judi N A van Diessen; Jose S A Belderbos; Egbert F Smit; Kim Monkhorst; Jan W A Oosterhuis; Michel M van den Heuvel; Max Dahele; Koen J Hartemink
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.